| Dr Michael Solomon Assefa, MD | |
|
303 Parkway Dr Ne, Atlanta, GA 30312-1212 | |
| (404) 265-6415 | |
| (404) 265-6488 |
| Full Name | Dr Michael Solomon Assefa |
|---|---|
| Gender | Male |
| Speciality | Hospitalist |
| Experience | 14 Years |
| Location | 303 Parkway Dr Ne, Atlanta, Georgia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1457849333 | NPI | - | NPPES |
| 100210088 | Medicaid | WI |
| Facility Name | Location | Facility Type |
|---|---|---|
| Northside Hospital Cherokee | Canton, GA | Hospital |
| Northside Hospital Gwinnett | Lawrenceville, GA | Hospital |
| Memorial University Medical Center | Savannah, GA | Hospital |
| Aurora Baycare Medical Ctr | Green bay, WI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| North Atlanta Professional Services Llc | 0840291944 | 296 |
| Cogent Healthcare Of Georgia Pc | 2961483607 | 255 |
| Baycare Aurora Llc | 0244130557 | 173 |
News Archive
As anxiety and depression rise in the country, primary care clinics, especially in rural areas, are facing increased patient needs.
Cell Therapeutics, Inc. (CTI) has announced that the U.S. Food and Drug Administration (FDA) has accepted for filing and review, and has granted priority review status for, the supplemental Biologics License Application (sBLA) for use of Zevalin ([90Y]-ibritumomab tiuxetan) as consolidation therapy for patients with follicular B-cell non-Hodgkin's lymphoma who achieve a response to first-line therapy. Priority review is granted by the FDA for a treatment that addresses a significant unmet medical need.
Millennium: The Takeda Oncology Company today announced data from clinical trials of four investigational compounds in solid tumors presented at the Annual Meeting of the American Society of Clinical Oncology, held in Chicago, Illinois, June 4-8, 2010. These data include an oral presentation on MLN8237, the Company's selective Aurora A kinase inhibitor.
Nicotine-free plastic inhalers may increase a smoker's chance of quitting, according to new research published online in the European Respiratory Journal.
› Verified 9 days ago
| Entity Name | Cogent Healthcare Of Georgia Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1609827823 PECOS PAC ID: 2961483607 Enrollment ID: O20040527000856 |
News Archive
As anxiety and depression rise in the country, primary care clinics, especially in rural areas, are facing increased patient needs.
Cell Therapeutics, Inc. (CTI) has announced that the U.S. Food and Drug Administration (FDA) has accepted for filing and review, and has granted priority review status for, the supplemental Biologics License Application (sBLA) for use of Zevalin ([90Y]-ibritumomab tiuxetan) as consolidation therapy for patients with follicular B-cell non-Hodgkin's lymphoma who achieve a response to first-line therapy. Priority review is granted by the FDA for a treatment that addresses a significant unmet medical need.
Millennium: The Takeda Oncology Company today announced data from clinical trials of four investigational compounds in solid tumors presented at the Annual Meeting of the American Society of Clinical Oncology, held in Chicago, Illinois, June 4-8, 2010. These data include an oral presentation on MLN8237, the Company's selective Aurora A kinase inhibitor.
Nicotine-free plastic inhalers may increase a smoker's chance of quitting, according to new research published online in the European Respiratory Journal.
› Verified 9 days ago
| Entity Name | North Atlanta Professional Services Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1316959869 PECOS PAC ID: 0840291944 Enrollment ID: O20070116000197 |
News Archive
As anxiety and depression rise in the country, primary care clinics, especially in rural areas, are facing increased patient needs.
Cell Therapeutics, Inc. (CTI) has announced that the U.S. Food and Drug Administration (FDA) has accepted for filing and review, and has granted priority review status for, the supplemental Biologics License Application (sBLA) for use of Zevalin ([90Y]-ibritumomab tiuxetan) as consolidation therapy for patients with follicular B-cell non-Hodgkin's lymphoma who achieve a response to first-line therapy. Priority review is granted by the FDA for a treatment that addresses a significant unmet medical need.
Millennium: The Takeda Oncology Company today announced data from clinical trials of four investigational compounds in solid tumors presented at the Annual Meeting of the American Society of Clinical Oncology, held in Chicago, Illinois, June 4-8, 2010. These data include an oral presentation on MLN8237, the Company's selective Aurora A kinase inhibitor.
Nicotine-free plastic inhalers may increase a smoker's chance of quitting, according to new research published online in the European Respiratory Journal.
› Verified 9 days ago
| Entity Name | Wellstar Medical Group, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1558664003 PECOS PAC ID: 6709065402 Enrollment ID: O20110127000374 |
News Archive
As anxiety and depression rise in the country, primary care clinics, especially in rural areas, are facing increased patient needs.
Cell Therapeutics, Inc. (CTI) has announced that the U.S. Food and Drug Administration (FDA) has accepted for filing and review, and has granted priority review status for, the supplemental Biologics License Application (sBLA) for use of Zevalin ([90Y]-ibritumomab tiuxetan) as consolidation therapy for patients with follicular B-cell non-Hodgkin's lymphoma who achieve a response to first-line therapy. Priority review is granted by the FDA for a treatment that addresses a significant unmet medical need.
Millennium: The Takeda Oncology Company today announced data from clinical trials of four investigational compounds in solid tumors presented at the Annual Meeting of the American Society of Clinical Oncology, held in Chicago, Illinois, June 4-8, 2010. These data include an oral presentation on MLN8237, the Company's selective Aurora A kinase inhibitor.
Nicotine-free plastic inhalers may increase a smoker's chance of quitting, according to new research published online in the European Respiratory Journal.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Michael Solomon Assefa, MD 303 Parkway Dr Ne, Atlanta, GA 30312-1212 Ph: (404) 265-6415 | Dr Michael Solomon Assefa, MD 303 Parkway Dr Ne, Atlanta, GA 30312-1212 Ph: (404) 265-6415 |
News Archive
As anxiety and depression rise in the country, primary care clinics, especially in rural areas, are facing increased patient needs.
Cell Therapeutics, Inc. (CTI) has announced that the U.S. Food and Drug Administration (FDA) has accepted for filing and review, and has granted priority review status for, the supplemental Biologics License Application (sBLA) for use of Zevalin ([90Y]-ibritumomab tiuxetan) as consolidation therapy for patients with follicular B-cell non-Hodgkin's lymphoma who achieve a response to first-line therapy. Priority review is granted by the FDA for a treatment that addresses a significant unmet medical need.
Millennium: The Takeda Oncology Company today announced data from clinical trials of four investigational compounds in solid tumors presented at the Annual Meeting of the American Society of Clinical Oncology, held in Chicago, Illinois, June 4-8, 2010. These data include an oral presentation on MLN8237, the Company's selective Aurora A kinase inhibitor.
Nicotine-free plastic inhalers may increase a smoker's chance of quitting, according to new research published online in the European Respiratory Journal.
› Verified 9 days ago
Dr. Tianna E. Johnson, D.O. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 35 Collier Rd Nw, Suite 635, Atlanta, GA 30309 Phone: 404-367-3014 Fax: 404-367-3558 | |
Dr. Maha Osman Sulieman, MBBS Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1364 Clifton Rd Ne, Atlanta, GA 30322 Phone: 404-712-2000 | |
Sarah Latif, M.D Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 35 Collier Rd Nw Ste 635, Atlanta, GA 30309 Phone: 404-367-3014 | |
Dr. Tait Thomas Jones, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1362 Clifton Rd Ne, Atlanta, GA 30322 Phone: 404-727-5658 | |
Candice Marie Delk, D.O. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 35 Collier Rd Nw, Suite 635, Atlanta, GA 30309 Phone: 404-367-3014 Fax: 404-367-3558 | |
Thara Mrithula Vidyasagaran, M.D Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1364 Clifton Rd Ne, Atlanta, GA 30322 Phone: 404-712-7100 | |
Matthew Jason Brown, Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 49 Jesse Hill Jr Dr Se, Atlanta, GA 30303 Phone: 404-778-7777 |